Biocon Limited (BSE: 532523) is an Indian biopharmaceutical company based in Bangalore, India. The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. In research services, Syngene International Limited (Syngene), a publicly listed subsidiary of Biocon, is engaged in the business of integrated end-to-end drug discovery and development services.

Property Value
dbo:abstract
  • Biocon Limited (BSE: 532523) is an Indian biopharmaceutical company based in Bangalore, India. The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. In research services, Syngene International Limited (Syngene), a publicly listed subsidiary of Biocon, is engaged in the business of integrated end-to-end drug discovery and development services. Biocon's formulations for the Indian market straddles Metabolics, Oncology, Immunotherapy, Nephrology and Specialty. Some of Biocon's key brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb(Itolizumab) and KRABEVA (Bevacizumab), which are claimed to be considerably less expensive than other leading brands. Two of its novel programs on the verge of proof-of-concept stage are IN-105, which is the only oral insulin in the world to be in long duration clinical trials, and T1h, a novel humanised monoclonal antibody (MAb), the only first-in-class novel MAb being tested in India for rheumatoid arthritis and psoriasis. Biocon and Syngene together employ about 9200 personnel including biologists, chemists, medical practitioners, pharmacologists, engineers, finance/legal/marketing analysts, HR generalists and general administrators. (en)
dbo:foundedBy
dbo:industry
dbo:keyPerson
dbo:numberOfEmployees
  • 9234 (xsd:integer)
dbo:product
dbo:thumbnail
dbo:type
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-09-14 07:46:23Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 1899802 (xsd:integer)
dbo:wikiPageLength
  • 42923 (xsd:integer)
dbo:wikiPageModified
  • 2019-09-14 07:46:10Z (xsd:date)
dbo:wikiPageOutDegree
  • 85 (xsd:integer)
dbo:wikiPageRevisionID
  • 915606540 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dbp:wordnet_type
dct:subject
rdf:type
rdfs:comment
  • Biocon Limited (BSE: 532523) is an Indian biopharmaceutical company based in Bangalore, India. The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. In research services, Syngene International Limited (Syngene), a publicly listed subsidiary of Biocon, is engaged in the business of integrated end-to-end drug discovery and development services. (en)
rdfs:label
  • Biocon (en)
owl:sameAs
foaf:depiction
foaf:isPrimaryTopicOf
foaf:name
  • Biocon Limited (en)
is dbo:wikiPageRedirects of
is foaf:primaryTopic of